Cigna scoops up Humana Medicare Advantage plans
Sale of plans in three Texas and Arkansas markets will help Humana satisfy its government-stipulated divestiture so that it can complete its acquisition of Arcadian Health.
Cigna will purchase Medicare Advantage plans in three markets in Texas and Arkansas from Humana. The sale comes on the heels of last year’s government stipulation that Humana divest some of its Medicare Advantage plans in order to complete its acquisition of Arcadian Health.
The plans in Amarillo and Longview-Marshall, Texas, and Texarkana, Ark., will move about 3,500 Humana or Arcadian members to Cigna’s HealthSpring on Jan. 1, 2013. HealthSpring, based in Nashville, already serves more than 1 million customers, but this allows it to extend into Arkansas for the first time and expand its current footprint in Texas.
“We welcome our new customers to our talented team of doctors and staff that have proudly served our customers for over a decade,” stated HealthSpring President Herb Fritch in a press release. “At HealthSpring, we dedicate significant resources to meet the individual needs of each and every one of our customers and we look forward to delivering our service to more Texas and Arkansas seniors.”
Go back to the Managed Healthcare Executive eNews newsletter.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
